Key facts
- Notable investors include Jintai Jinhong Investment, Shanghai Biomedical Public Technology, Xinrui Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ENSKBio
- ·The full record, as it builds
Funding rounds
No funding rounds for ENSKBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ENSKBio
Provider of cell therapy solutions designed to advance stem cell innovation in medicine. The company applies cell therapy technology to drug development for chronic diseases such as diabetes and collaborates with leading tertiary hospitals on clinical applications.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Website
- enskbio.com/
- Ownership
- Privately Held (backing)
ENSKBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ENSKBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ENSKBio in its N-PORT filings yet. We sweep new filings monthly.